Search
albiglutide (Tanzeum)
Indications:
- diabetes mellitus type 2
- for use as monotherapy or in combination with
- metformin, glimepiride, pioglitazone, or insulin
Contraindications:
- personal or family history of
- medullary thyroid carcinoma
- multiple endocrine neoplasia syndrome type 2
Dosage:
- once-weekly injectable
Adverse effects:
- diarrhea
- nausea
- injection-site reactions
- boxed warning:
- thyroid C-cell tumors (medullary thyroid carcinoma) have been observed in rodent studies with some drugs in this class
Mechanism of action:
- glucagon-like peptide 1 receptor agonist
Notes:
- manufactured by GlaxoSmithKline, L.L.C., Wilmington, Del.
Interactions
drug adverse effects of hypoglycemic agents
General
glucagon-like peptide 1 (GLP-1) receptor agonist; incretin mimetic; GLP-1 mimetic; GLP-1 agonist; glutide; GLP-1RA
References
- Busko M
FDA Approves Weekly Injectable Diabetes Drug: Albiglutide
Medscape: April 15, 2014
http://www.medscape.com/viewarticle/823645
- FDA News Release: April 15, 2014
FDA approves Tanzeum to treat type 2 diabetes.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm393289.htm
- Prescriber's Letter 21(8): 2014
CHART: Comparison of GLP-1 Agonists
Detail-Document#: 300824
(subscription needed) http://www.prescribersletter.com